MVA MERS Vaccine Description
MVA MERS (Modified Vaccinia virus Ankara) is a vaccine candidate that contains the full-length spike gene of MERS-CoV.
MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene
MVA MERS Vaccine Indication
MVA MERS (Modified Vaccinia virus Ankara) is a vaccine candidate to treat Middle East respiratory syndrome (MERS).
MVA MERS Vaccine Dosage
Dosage is being tested in Clinical Trials
MVA MERS Vaccine Clinical Trials
Clinical Trial NCT04119440: Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF-1 (Not yet recruiting)
This will be a Phase Ib, a two-center study in approximately 160 healthy adults aged 18-55 years
The study is separated into two parts
- Part A
- The study starts with a single-center open-label run-in phase of two dose levels (cohort 1 "low dose": 2x10^7 PFU, cohort 2 "high dose": 2x10^8 PFU) in 10 healthy subjects. 5 subjects will be allocated to each dose cohort and will receive immunization on day 0 and day 28.
- Part B
- Two-center, randomized, double-blind, placebo-controlled, dose-finding study. This part is a double-blinded trial in approximately 150 healthy subjects. Subjects will be allocated to two different dose cohorts and a placebo cohort; each receiving three vaccine injections.
Clinical Trial NCT03615911: Safety, Tolerability, and Immunogenicity of Vaccine Candidate MVA-MERS-S
- The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a potentially fatal disease with a reported lethality of up to 40% that is under tight epidemiologic control by the World Health Organization (WHO) and currently without registered prevention or treatment option.
- In this phase I first-in-human clinical trial, healthy volunteers in two different dose cohorts will be vaccinated twice with the candidate vaccine MVA-MERS-S. A subgroup will additionally receive a late booster vaccination.
- The aim of the study is to assess the safety and tolerability of the candidate vaccine and to characterize its immunogenicity.
- The vaccine contains a Modified Vaccinia Virus Ankara (MVA) vector expressing the MERS-CoV spike glycoprotein (S). A total of 24 participants will receive the following vaccine regime:
- 12 participants will receive 10^7 plaque-forming units (PFU) of MVA-MERS-S on days 0 and 28.
- 12 participants will receive 10^8 PFU of MVA-MERS-S on days 0 and 28.
- Safety and immunogenicity data will be collected throughout the study, which concludes at day 180.
Update March 2019: A subgroup of participants from both dose cohorts will receive a late booster immunization of 10^8 PFU MVA-MERS-S 9 months (+/- 4 months) after prime immunization.